← Back to headlines
Summit Therapeutics Stock Surges 28% on Clinical Progress for Ivonescimab
Shares of Summit Therapeutics jumped significantly after the company reported positive developments regarding its experimental drug ivonescimab.
7 Sept, 05:53 — 7 Sept, 05:53
Sources
Showing 1 of 1 sources
